MG132

(S)-MG132 is a potent, reversible and cell permeable proteasome inhibitor that inhibits cell growth in B16 and IPC227F cells with IC₅₀ values of 42 and 77 nM, respectively.¹ (S)-MG132 at 10 µM inhibits NF-κB activation, sensitizing a variety of carcinoma cell lines to apoptosis.²

WARNING This product is not for human or veterinary use.

1. Vivier, M., Rapp, M., Papon, J., et al. Synthesis, radiosynthesis, and biological evaluation of new proteasome inhibitors in a tumor targeting approach. J. Med. Chem. 51(4), 1043-1047 (2008).

2. Arlt, A., Vorndamm, J., Breitenbroich, M., et al. Inhibition of NF- k B sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20, 859-868 (2001).

Lao, L., Bourdeau, I., Gagliardi, L., et al. ARMC5 is part of an RPB1-specific ubiquitin ligase implicated in adrenal hyperplasia. Nucleic Acids Res. 50(11), 6343-6367 (2022).

Jiang, S.-Y., Li, H., Tang, J.-J., et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nat. Commun. 9:5138, (2018).

Tsuda, S., Shinohara, M., Oshita, T., et al. Novel mechanism of regulation of the 5-lipoxygenase/leukotriene B₄ pathway by high-density lipoprotein in macrophages. Sci. Rep. 7(1), 12989 (2017).